MDACC Study No:2008-0059 ( NCT No: NCT00734526)
Title:A Phase I/II Study of Sorafenib with Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
Principal Investigator:Vinay K. Puduvalli
Treatment Agent:Sorafenib; Temozolomide
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of sorafenib that can be given in combination with temozolomide. The safety of
this combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I/Phase II
Treatment Agents:Sorafenib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Bayer
Return Visit:every 4 weeks
Home Care:Patients will take the study drug orally at home

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Vinay K. Puduvalli
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults